Literature DB >> 21195796

Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis.

Sandro Ardizzone1, Andrea Cassinotti, Piergiorgio Duca, Cristina Mazzali, Chiara Penati, Gianpiero Manes, Riccardo Marmo, Alessandro Massari, Paola Molteni, Giovanni Maconi, Gabriele Bianchi Porro.   

Abstract

BACKGROUND & AIMS: It is uncertain whether mucosal healing after the first course of corticosteroids therapy predicts outcome in patients with ulcerative colitis (UC). We evaluated whether early clinical and endoscopic responses to this therapy are associated with late outcomes in UC.
METHODS: Patients with newly diagnosed UC who were prescribed corticosteroid therapy (n = 157) were followed up for 5 years. They were evaluated using clinical (Powel-Tuck [PT]) and endoscopic (Baron) indexes after 3 and 6 months, then every 6 months. Outcomes at month 3 (early response) were used to identify patients with complete (group A: PT, 0-1; Baron, 0), partial (group B: PT, 0-1; Baron, 1-3), or no response (group C: persistence of clinical and endoscopic activity). The association between early and late outcomes was assessed.
RESULTS: After 5 years, there were significant differences between complete and partial responders in the rates of hospitalization (25% in group A vs 48.7% in group B; P = .0152; odds ratio [OR], 2.85; 95% confidence interval [CI], 1.21-6.72), immunosuppression therapy (5% in group A vs 25.6% in group B; P = .0030; OR, 6.55; 95% CI, 1.67-25.67), colectomy (3.3% in group A vs 18.0% in group B; P = .0265; OR, 6.34; 95% CI, 1.24-32.37), and their combination (26.7% in group A vs 48.7% in group B; P = .0249; OR, 2.61; 95% CI, 1.12-6.11). After multivariate analysis, lack of mucosal healing was the only factor associated with negative outcomes at 5 years (immunosuppressors: hazard risk [HR], 10.581; 95% CI, 2.193-51.039; P = .0033; hospitalization: HR, 3.634; 95% CI, 1.556-8.485; P = .0029; colectomy: HR, 8.397; 95% CI, 1.278-55.186; P = .0268).
CONCLUSIONS: No mucosal healing after corticosteroid therapy is associated with a more aggressive disease course.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21195796     DOI: 10.1016/j.cgh.2010.12.028

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  74 in total

1.  Predictors of aggressive inflammatory bowel disease.

Authors:  Andres J Yarur; Sebastian G Strobel; Amar R Deshpande; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

Review 2.  Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice.

Authors:  Britt Christensen; David T Rubin
Journal:  Curr Gastroenterol Rep       Date:  2016-01

Review 3.  Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.

Authors:  Antonio Di Sabatino; Lucio Liberato; Monia Marchetti; Paolo Biancheri; Gino R Corazza
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

4.  The role of mucosal healing in the treatment of patients with inflammatory bowel disease.

Authors:  Byron P Vaughn; Sveta Shah; Adam S Cheifetz
Journal:  Curr Treat Options Gastroenterol       Date:  2014-03

5.  Point-counterpoint: Are we overtreating patients with mild ulcerative colitis?

Authors:  Akbar K Waljee; Ryan W Stidham; Peter D R Higgins; Sandeep Vijan; Sameer D Saini
Journal:  J Crohns Colitis       Date:  2013-08-12       Impact factor: 9.071

6.  Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse.

Authors:  Asuka Nakarai; Jun Kato; Sakiko Hiraoka; Shiho Takashima; Daisuke Takei; Toshihiro Inokuchi; Yuusaku Sugihara; Masahiro Takahara; Keita Harada; Hiroyuki Okada
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

7.  Risks of Infection among the Older Inflammatory Bowel Disease Patients.

Authors:  Christina Y Ha
Journal:  Curr Treat Options Gastroenterol       Date:  2014-09

8.  Molecular patterns in human ulcerative colitis and correlation with response to infliximab.

Authors:  Brendan Halloran; Jessica Chang; David Q Shih; Dermot McGovern; Konrad Famulski; Chad Evaschesen; Richard N Fedorak; Aducio Thiesen; Stephan Targan; Philip F Halloran
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

Review 9.  [What rheumatologists can learn from gastroenterologists].

Authors:  S Fischer; C Beyer; M F Neurath
Journal:  Z Rheumatol       Date:  2018-08       Impact factor: 1.372

Review 10.  Ulcerative Colitis: Update on Medical Management.

Authors:  Heba N Iskandar; Tanvi Dhere; Francis A Farraye
Journal:  Curr Gastroenterol Rep       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.